Second site open in the USA for EDELIFE Clinical Trial

We are thrilled to announce the opening of a new clinical site in the United States, bringing the total number of sites for the EDELIFE clinical trial to eight, spanning six countries. Cedars-Sinai Medical Center in Los Angeles, California, has been chosen as a second location to complement the existing site at Washinghton University in St Louis, Missouri. By adding a new location, we aim to make the Edelife study more geographically accessible and provide more opportunities for potential patients to participate.  

In partnership with Pierre Fabre, EspeRare Foundation is leading this groundbreaking study, which has been welcomed by healthcare professionals and patient communities. The EDELIFE clinical trial aims to address a significant unmet need, as there is currently no curative treatment available for XLHED (X-linked hypohidrotic ectodermal dysplasia).

Recruitment is ongoing across Europe and the USA to enroll women who know or suspect they are carriers of XLHED and are pregnant with a boy. Clinical sites are now open in the UK, Germany, France, Italy, Spain, and the USA.

However, women in any country who meet the criteria may still have the opportunity to join this pivotal study.

https://edelifeclinicaltrial.com/ to find out more